LINTHICUM, Md., Dec. 21, 2004 (PRIMEZONE) -- Dialysis Corporation of America (Nasdaq:DCAI) announced the opening of a new facility in Ashland, Virginia, the company's second in the state. The company had previously announced the development of this facility in conjunction with Richmond Nephrology Associates.
Company president and CEO Stephen Everett commented, "We are excited about the addition of this center which will serve patients in the greater Richmond area. The opening of this center reflects our continuing expansion efforts in Virginia and the Mid-Atlantic region as a whole, and is consistent with our strategic growth plans." The new state-of-the-art facility has been designed to enhance patient comfort and safety, and is centrally located for easy patient access and convenience. The facility has 15 patient treatment stations, as well as a peritoneal suite for patients seeking that form of dialysis treatment.
Also as previously announced, the company is in development of a new facility in the Cincinnati, Ohio area.
Dialysis Corporation of America currently owns or manages 23 freestanding kidney hemodialysis centers located in Georgia, Maryland, New Jersey, Ohio, Pennsylvania, South Carolina and Virginia, providing patients with a full range of quality in-center and at-home dialysis services, as well as providing in-hospital dialysis services on a contract basis to certain hospitals located in those states.
This release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results and plans to differ materially from those anticipated. Those factors include, but are not limited to, certain delays beyond the company's control with respect to future business events, the highly competitive environment in the establishment and operation of dialysis centers, the ability to develop or acquire additional dialysis facilities, whether patient bases of the company's facilities can expand to provide profitability, regulation of dialysis operations, government rate determination for Medicare reimbursement, and other risks detailed in the company's filings with the Securities and Exchange Commission, particularly as described in the company's annual report on Form 10-K for the fiscal year ended December 31, 2003.
Other Dialysis Corporation of America press releases, a corporate profile, corporate governance materials, and the most recent annual report on Form 10-K for the year ended December 31, 2003, and other filings with the Securities and Exchange Commission are available through Dialysis Corporation of America's internet home page: http://www.dialysiscorporation.com.